Lv4
540 积分 2021-02-19 加入
Taletrectinib: TRUST in the Continued Evolution of Treatments for ROS1 Fusion-Positive Lung Cancer
8天前
已完结
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
2个月前
已完结
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
2个月前
已完结
Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review
4个月前
已完结
Analysis of adverse events with sclerosants reported to the United States Food and Drug Administration
7个月前
已完结
皖公网安备34019202002308
